A low advertised medication price answers a purchasing question, not an evidence question. Collective lists compounded semaglutide at $59 per month and compounded tirzepatide at $69 per month, plus a $199 annual membership. For someone evaluating those offers, the important next step is to separate three things: what the platform promises to arrange, what its independent medical and pharmacy partners are responsible for, and what published clinical research can actually establish about the product eventually prescribed.
This review examines Collective’s public commercial pages, terms and privacy policy, consulted October 19, 2026. Two substantially duplicated commercial pages should not be mistaken for independent corroboration. The documents support classifying Collective as a platform facilitating GLP-1 access, but not as the medical practice delivering that care. They also leave important product details unresolved. Our focus is documentary evidence: which claims are explicit, where contractual qualifications matter, and which questions require answers from the actual prescriber or dispensing pharmacy.
At a glance
- Platform, not medical practice
- Health for Everyone Inc., doing business as CollectiveOS, facilitates access through independent healthcare providers and pharmacies; its terms say it does not provide or control medical care.
- Published medication and membership prices
- Collective advertises compounded semaglutide at $59/month and compounded tirzepatide at $69/month, at the same price for any dose, plus a separate $199 annual membership.Sources: [7]
- Trial is not free medication
- The commercial offer provides 21 days without a membership charge while medication remains payable. The terms qualify trial eligibility and access to platform features.
- Geographic restrictions
- Collective reports availability in 44 states, excluding Alabama, California, Louisiana, Massachusetts, Mississippi and Washington. Its terms exclude users outside the United States.
- Quality claims have documentation limits
- Collective says prescriptions are filled by state-licensed US pharmacies and every batch receives third-party purity and potency testing; the reviewed documentation does not name those pharmacies or provide testing certificates.Sources: [7]
Start with who is making each promise
The published legal identity is Health for Everyone Inc., doing business as CollectiveOS, with a mailing address at 1940 Fountain View Dr, PMB 3077, Houston, Texas 77057. Collective is the consumer-facing brand. Its terms describe a membership-based platform facilitating telehealth consultations and prescription wellness products, including GLP-1s and peptides. That establishes a commercial intermediary model, not a single organization performing every step from assessment through dispensing.
The distinction is unusually explicit: CollectiveOS says it is not a medical provider or group, does not employ or supervise the treating clinicians, and does not control their care. Its privacy policy names MDIntegrations and its network of independent medical groups as examples of consultation partners. That reference does not establish which particular practice would treat an individual member, or verify the credentials of a particular clinician.
For readers, the useful evidence question is therefore not simply whether Collective offers messaging or prescribing access. It is which entity will review the assessment, maintain the clinical record, issue a prescription and respond to medical concerns. Our guide to what public provider documents can prove explains this distinction. Here, the terms establish divided responsibilities more clearly than the commercial pages identify each responsible organization.
The product names do not supply the missing formulation details
Collective explicitly advertises compounded semaglutide and compounded tirzepatide. However, the reviewed documentation does not specify administration route, presentation, additional ingredients or the quantity supplied with each shipment. Those omissions matter when connecting a commercial offer to published research. A familiar ingredient name alone does not establish that a preparation matches a studied product, its delivery method or its manufacturing and quality documentation.
FDA states that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That is not, by itself, proof of clinical inequivalence or a judgment that this platform is unsafe. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Approval applies to a particular product, not to a platform’s overall reputation.
Collective also says every batch is third-party tested for purity and potency. The reviewed pages do not provide certificates, identify the testing organization or name the dispensing pharmacies. The claim is relevant, but it remains a provider assertion rather than independently examined batch evidence. Before paying, ask for the exact formulation and pharmacy identity; our explanation of approved medicines and compounded preparations outlines why those are separate evidence questions.
Clinical research is not a Collective performance report
The clinical research consulted for this review includes STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide. Neither trial studied Collective or its compounded preparations. Their results therefore cannot establish the outcomes of joining this platform. Because Collective’s public documentation leaves formulation and route unresolved, presenting trial weight-loss percentages beside its prices would suggest a connection that these documents do not substantiate.
Likewise, the commercial pages’ broad benefits and safety language should not be treated as measured outcomes for Collective members. The reviewed documentation does not establish a provider-specific clinical effectiveness rate. This distinction does not erase the underlying medication research; it defines its scope. Our guide explaining why a clinical trial is not a telehealth company performance report addresses this common leap from drug research to company marketing.
A more meaningful discussion with the treating clinician would connect the proposed preparation to the person’s health conditions, other medicines, potential side effects and costs. NIDDK describes medication selection as an individualized decision and treatment as accompanying healthy eating and physical activity. Collective’s promised nutrition and lifestyle services fit that general care framework, but the existence of support services does not demonstrate their effectiveness or predict an individual’s response.
Read the price as separate charges, not one all-inclusive number
The published medication prices are concrete: $59 per month for compounded semaglutide and $69 per month for compounded tirzepatide, advertised as unchanged across doses. Medication is billed separately from the $199 annual membership. Collective also advertises that multi-month orders are not required. These statements do not specify the quantity in a shipment, establish a minimum treatment commitment or justify assuming a particular route or presentation.
The membership is advertised as covering personalized doctor-prescribed protocols, unlimited doctor messaging, ongoing check-ins and adjustments, nutrition and lifestyle support, and express cold shipping. Collective says it does not bill insurance. Medication and membership may qualify for HSA/FSA reimbursement, but the plan administrator decides. That is a potential reimbursement pathway, not a promise of eligibility, direct account acceptance or a particular tax outcome.
One material tension deserves attention: the commercial page presents the structure as having nothing added on top, while the terms permit a nominal, uniform technology transaction fee for each electronic prescription transmission, regardless of pharmacy. No amount or precise application conditions are disclosed. The documents also do not resolve possible charges for later laboratory work, ancillary medication or supplies. Those gaps warrant an itemized checkout explanation, not an assumption that every possible service is included.
| Item | Documented offer | Important qualification |
|---|---|---|
| Compounded semaglutide | $59/month; same advertised price at any dose | Separate $199 annual membership; route and supply quantity unspecified |
| Compounded tirzepatide | $69/month; same advertised price at any dose | Separate $199 annual membership; route and supply quantity unspecified |
| Membership trial | 21 days without a membership charge | Medication is paid; terms qualify eligibility and available features |
| Annual membership | $199/year after the trial | Automatically renews unless canceled before the current period ends |
| Prescription transmission | Terms allow a uniform technology transaction fee | Amount and application circumstances are not specified |
Enrollment and renewal require reading beyond the trial headline
The commercial invitation is 21 days free of membership charges, with medication paid during that window. It says canceling before the 21 days end avoids the annual membership charge. The terms are narrower: new users may be eligible for a limited trial covering certain platform features, as described at sign-up. A prospective member should therefore confirm the actual offer presented to their account rather than assume universal access to every advertised feature.
After purchase, membership renews automatically each year unless canceled online before the current membership period ends. Collective advertises account-based cancellation without phone calls. Cancellation leaves the account active through the paid period, but membership fees and partial periods are generally nonrefundable, except where required by applicable law or expressly stated at purchase. The ability to stop a future renewal is not the same as recovering a payment already collected.
The refund language also has separate boundaries. The commercial page promises a full refund if the doctor determines treatment is inappropriate and says members are not charged for medication they do not receive. Meanwhile, the general terms make products and services nonreturnable and nonrefundable except at CollectiveOS’s discretion. Advertising also describes a locked price, while the terms permit membership price changes with advance communication, effective at the next membership period. Written checkout terms should clarify these differences.
The intake pathway is described; full eligibility criteria are not
Collective describes a brief online health assessment covering medical history, goals and previous GLP-1 experience. Its commercial page says a US-licensed physician usually reviews it within one or two days, with no in-person visit or laboratory work needed to begin. This is a description of the advertised starting process, not proof that no examination, testing or additional information could be needed later.
The terms require a completed consultation, a provider’s determination that the prescription product is appropriate, and an issued prescription before a user can obtain it. Access is therefore not a guaranteed prescription. The reviewed pages do not establish complete BMI, comorbidity, contraindication or approval criteria. Existing GLP-1 users are offered transition support and possible continuation of their current dose only with doctor approval; switching between treatments likewise requires approval.
Location is more explicit than clinical eligibility: Collective reports serving 44 states, excluding Alabama, California, Louisiana, Massachusetts, Mississippi and Washington. The terms also exclude users outside the United States. Age language is less consistent: the terms reference parental permission for under-18 users, while the privacy policy says minors may not submit personal information. This adult-focused review does not resolve that conflict or establish pediatric treatment availability.
Pharmacy choice and cold shipping leave operational questions
Collective says every prescription is written by a US-licensed doctor and filled by a state-licensed US pharmacy. Those are company statements, not independent licensing verification. Its terms allow patients to fill prescriptions at a pharmacy of their choice, as prompted during the service. That permission does not establish that any outside pharmacy will offer the advertised preparation, charge Collective’s published price or include the same shipping arrangements.
After approval, the commercial page advertises cold-shipped two-day express delivery to the home, with express cold shipping included in membership. The usual one- or two-day clinical review and the two-day shipping service describe different stages. They do not promise receipt two days after applying. The reviewed documents do not provide a total application-to-arrival timeline, carrier details, order-preparation time or clear replacement procedures for lost or temperature-compromised shipments.
For an injectable GLP-1 product, FDA explicitly advises not using it if it arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. That guidance is important even though Collective’s advertised route is not specified in the reviewed pages. Before ordering, establish who handles delivery concerns and how to reach them. Our guide to reading cold-chain and delivery claims separates a shipping promise from evidence of appropriate arrival conditions.
Follow-up and privacy cross organizational boundaries
The advertised follow-up package includes unlimited doctor messaging, quarterly check-ins, live group question-and-answer sessions with registered dietitians, and practical nutrition and lifestyle resources. These are specific offerings rather than simply a promise of general support. However, the reviewed documentation does not establish messaging hours, response-time standards or Spanish-language availability. Unlimited messaging describes access volume; it does not establish immediate clinical availability or emergency coverage.
The terms expressly exclude emergencies and urgent situations and recommend maintaining a local primary care relationship. That limits how the online service should be understood: it is not a replacement for all ongoing medical care. The published email questions@collective.org and phone number (832) 280-7898 appear as help contacts in messaging-related language. Their publication does not establish that either channel is a clinician line or an urgent medical response service.
Privacy responsibilities are similarly divided. The privacy policy says protected health information associated with consultations and prescription fulfillment is governed by health privacy laws and the provider’s privacy notice. It also permits sharing personal information with pharmacy, telehealth, payment, logistics, hosting, analytics and support partners, subject to stated contractual restrictions. A useful preparation step is to obtain the treating practice’s privacy notice and identify where clinical questions, records requests and platform account questions should each go.
Questions & answers
Is Collective itself the prescribing medical practice?
No. Its terms describe CollectiveOS as a platform facilitating access to independent providers and pharmacies, not as a medical provider. The privacy policy mentions MDIntegrations and its network as examples of consultation partners. Ask which specific medical practice will treat you and which pharmacy will dispense before assuming the Collective brand identifies every organization responsible for your care.
Does the $59 or $69 price include membership?
No. Those are separately billed monthly medication prices for compounded semaglutide and compounded tirzepatide, respectively. The advertised membership is $199 annually after the qualifying trial. Membership includes listed support and shipping services, but the terms also permit an unspecified prescription-transmission technology fee. Request an itemized explanation of what will be collected initially and what will recur.
What is actually free during the 21-day trial?
The commercial offer waives the membership charge during that window, not the medication charge. It says cancellation before the trial ends avoids the annual membership fee. The terms limit the offer to new users who may qualify and to certain platform features. Confirm your account’s eligibility, trial expiration and cancellation instructions at enrollment rather than treating the headline as an unconditional offer.
Does Collective provide proof of batch testing?
Collective states that every batch undergoes third-party purity and potency testing, but the reviewed documentation does not include certificates or identify the testing organization. It also does not name dispensing pharmacies. Ask the actual pharmacy what documentation applies to your preparation. A commercial testing claim is useful information to investigate, but it is not the same as independently reviewed product evidence.
Can I cancel and receive a refund?
Cancellation is available online, and the account remains active through the paid period. Membership fees and partial periods are generally nonrefundable, subject to the stated exceptions. Separately, the commercial page promises a full refund following a doctor’s determination that treatment is inappropriate. Ask which charges that promise covers; do not assume ordinary cancellation triggers the same refund or overrides all product and service restrictions.
Can I transfer an existing GLP-1 prescription without changing treatment?
Collective advertises transition support and the possibility of keeping a current dose if its doctor approves. That is conditional, not a guarantee of identical treatment or automatic acceptance of an existing prescription. Its intake asks about previous GLP-1 experience, and prescribing still requires consultation and a suitability decision. Confirm the exact proposed formulation, pharmacy and transition process with the treating clinician.
Our assessment
Collective’s documentation offers a reasonably clear outline of its commercial model: separately priced compounded medications, an annual membership, an online assessment, independent prescribing and dispensing, and specified follow-up services. The strongest documentary detail concerns purchasing and access, not demonstrated clinical outcomes. Important unresolved points include exact formulation and supply, named pharmacies, accessible batch-testing evidence, the possible technology fee and operational response standards. Published medication trials cannot fill those gaps or establish results for Collective’s preparations. For an adult considering the platform, the most useful next step is a written, itemized offer paired with identification of the actual clinician and pharmacy, product-specific information and clear refund and delivery procedures. Those answers would make the decision better informed without turning either attractive pricing or incomplete documentation into a clinical verdict.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Collective / CollectiveOS — legal/privacy ↗
- Collective / CollectiveOS — legal/terms of use ↗
- Collective / CollectiveOS — official website ↗